HCW Biologics Inc. has announced that it entered into a Securities Purchase Agreement with Armistice Capital Master Fund Ltd. on May 13, 2025. As part of the agreement, Armistice has been granted pre-funded warrants to purchase up to 513,140 shares of HCW Biologics' common stock at an exercise price of $0.0001 per share. On May 15, 2025, Armistice exercised some of these warrants, acquiring 177,140 shares, and further exercised additional warrants for 126,000 shares on May 21, 2025. As of May 22, 2025, Armistice retains the option to purchase an additional 210,000 shares.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-076994), on May 23, 2025, and is solely responsible for the information contained therein.